La Jolla Pharma Drug Patent Portfolio
La Jolla Pharma owns 1 orange book drug protected by 11 US patents Given below is the list of La Jolla Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11219662 | Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II | 06 Jan, 2037 | Active |
| US10028995 | Angiotensin II alone or in combination for the treatment of hypotension | 18 Dec, 2034 | Active |
| US10493124 | Angiotensin II alone or in combination for the treatment of hypotension | 18 Dec, 2034 | Active |
| US11096983 | Angiotensin II alone or in combination for the treatment of hypotension | 18 Dec, 2034 | Active |
| US11559559 | Angiotensin II alone or in combination for the treatment of hypotension | 18 Dec, 2034 | Active |
| US9220745 | Angiotensin II alone or in combination for the treatment of hypotension | 18 Dec, 2034 | Active |
| US9572856 | Method of treating low blood pressure | 18 Jul, 2031 | Active |
| US10335451 | Method of treating low blood pressure | 16 Dec, 2029 | Active |
| US10500247 | Method of treating low blood pressure | 16 Dec, 2029 | Active |
| US10548943 | Method of treating low blood pressure | 16 Dec, 2029 | Active |
| US9867863 | Method of treating low blood pressure | 16 Dec, 2029 | Active |
Latest Legal Activities on La Jolla Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of La Jolla Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 04 Aug, 2023 | US10548943 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Jun, 2023 | US9220745 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Jun, 2023 | US10500247 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Jun, 2023 | US10493124 |
| Sequence Moved to Public Database | 24 Jan, 2023 | US11559559 |
|
Recordation of Patent Grant Mailed
Critical
| 24 Jan, 2023 | US11559559 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 24 Jan, 2023 | US11559559 |
|
Email Notification
Critical
| 05 Jan, 2023 | US11559559 |
|
Issue Notification Mailed
Critical
| 04 Jan, 2023 | US11559559 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jan, 2023 | US10335451 |
| Dispatch to FDC | 30 Dec, 2022 | US11559559 |
|
Application Is Considered Ready for Issue
Critical
| 30 Dec, 2022 | US11559559 |
|
Issue Fee Payment Received
Critical
| 15 Dec, 2022 | US11559559 |
|
Issue Fee Payment Verified
Critical
| 15 Dec, 2022 | US11559559 |
| Sequence Forwarded to Pubs on Tape | 30 Nov, 2022 | US11559559 |
La Jolla Pharma's Family Patents
La Jolla Pharma drugs have patent protection in a total of 23 countries. It's US patent count contributes only to 37.7% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
La Jolla Pharma Drug List
Given below is the complete list of La Jolla Pharma's drugs and the patents protecting them.
1. Giapreza
Giapreza is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11219662 | Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II |
06 Jan, 2037
(12 years from now)
| Active |
| US10028995 | Angiotensin II alone or in combination for the treatment of hypotension |
18 Dec, 2034
(10 years from now)
| Active |
| US10493124 | Angiotensin II alone or in combination for the treatment of hypotension |
18 Dec, 2034
(10 years from now)
| Active |
| US11096983 | Angiotensin II alone or in combination for the treatment of hypotension |
18 Dec, 2034
(10 years from now)
| Active |
| US11559559 | Angiotensin II alone or in combination for the treatment of hypotension |
18 Dec, 2034
(10 years from now)
| Active |
| US9220745 | Angiotensin II alone or in combination for the treatment of hypotension |
18 Dec, 2034
(10 years from now)
| Active |
| US9572856 | Method of treating low blood pressure |
18 Jul, 2031
(6 years from now)
| Active |
| US9572856 | Method of treating low blood pressure |
20 Nov, 2030
(5 years from now)
| Active |
| US10335451 | Method of treating low blood pressure |
16 Dec, 2029
(5 years from now)
| Active |
| US10500247 | Method of treating low blood pressure |
16 Dec, 2029
(5 years from now)
| Active |
| US10548943 | Method of treating low blood pressure |
16 Dec, 2029
(5 years from now)
| Active |
| US9867863 | Method of treating low blood pressure |
16 Dec, 2029
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Giapreza's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List